In Brazil, the blood grouping reagents market was valued at $0.17 per capita in 2023. Forecasts project a consistent decline from $0.16 per capita in 2024 to $0.13 by 2028. This indicates an overall negative compound annual growth rate (CAGR) over the five-year forecast period. The year-on-year variations reveal a steady drop, with each year decreasing by approximately six to seven percent until stabilization in 2027 and 2028.
Future trends to watch include potential advancements in technology that may drive efficiency and reduce costs, influencing market dynamics. Additionally, regulatory changes and healthcare policies could impact future market conditions and behaviors in Brazil.
